Juergen A. Martens

Nessuna posizione attualmente

68 anni

Health Technology

Consumer Services

Profilo

Juergen A.
Martens worked as VP-Pharmaceutical Technology Development at Nektar Therapeutics from 2000 to 2005.
He then worked as Chief Operating Officer at MannKind Corp.
from 2015 to 2016, and as Chief Operations & Technology Officer at Neos Therapeutics, Inc. from 2016 to 2017.
Martens received his undergraduate degree from Mannheim Technical College, and his graduate and doctorate degrees from Philipps University of Marburg.
He also received a graduate degree from the University of Pennsylvania.

Precedenti posizioni note di Juergen A. Martens

Società	Posizione	Fine
NEOS THERAPEUTICS, INC.	Direttore operativo	30/06/2017
MANNKIND CORPORATION	Direttore operativo	18/03/2016
NEKTAR THERAPEUTICS	Direttore Tecnico/Scientifico/R&S	01/08/2005

Vedi nel dettaglio l'esperienza di Juergen A. Martens

Formazione di Juergen A. Martens

Philipps University of Marburg	Doctorate Degree
Mannheim Technical College	Undergraduate Degree
University of Pennsylvania	Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Juergen A. Martens

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
MANNKIND CORPORATION	Health Technology
NEKTAR THERAPEUTICS	Health Technology

Aziende private	1
Neos Therapeutics, Inc. Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.	Health Technology